Mark Lee - Ocumetics Technology Pres CEO
| OTC Stock | 0.32 0.01 3.23% |
Insider
Mark Lee is Pres CEO of Ocumetics Technology Corp
| Address | 639-5th Avenue SW, Calgary, AB, Canada, T2P 0M9 |
| Phone | 403-650-7718 |
| Web | https://ocumetics.com |
Mark Lee Latest Insider Activity
Tracking and analyzing the buying and selling activities of Mark Lee against Ocumetics Technology stock is an integral part of due diligence when investing in Ocumetics Technology. Mark Lee insider activity provides valuable insight into whether Ocumetics Technology is net buyers or sellers over its current business cycle. Note, Ocumetics Technology insiders must abide by specific rules, including filing SEC forms every time they buy or sell Ocumetics Technology'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Mark Lee over a year ago Payment of 52114 shares by Mark Lee of Forge Global subject to Rule 16b-3 |
Ocumetics Technology Management Efficiency
The company has return on total asset (ROA) of (0.7887) % which means that it has lost $0.7887 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (11.2268) %, meaning that it generated substantial loss on money invested by shareholders. Ocumetics Technology's management efficiency ratios could be used to measure how well Ocumetics Technology manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to climb to -9.14 in 2024. Return On Capital Employed is likely to climb to -8.3 in 2024. At this time, Ocumetics Technology's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to climb to about 784.3 K in 2024, whereas Total Current Assets are likely to drop slightly above 202.3 K in 2024.Similar Executives
| Found 11 records | INSIDER Age | ||
| Hirotaka Katagiri | VentriPoint Diagnostics | N/A | |
| Jim Graba | VentriPoint Diagnostics | N/A | |
| CPA CMA | VentriPoint Diagnostics | 54 | |
| Don Kirk | CHAR Technologies | N/A | |
| Silvia Merlini | CHAR Technologies | N/A | |
| Jessica Naman | VentriPoint Diagnostics | N/A | |
| CPA CFA | CHAR Technologies | 60 | |
| Lewis Smith | CHAR Technologies | N/A | |
| BASc ICDD | VentriPoint Diagnostics | 70 | |
| Andrew White | CHAR Technologies | N/A | |
| Desmond Hirson | VentriPoint Diagnostics | N/A | |
Management Performance
| Return On Equity | -11.23 | ||||
| Return On Asset | -0.79 |
Ocumetics Technology Corp Leadership Team
Elected by the shareholders, the Ocumetics Technology's board of directors comprises two types of representatives: Ocumetics Technology inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Ocumetics. The board's role is to monitor Ocumetics Technology's management team and ensure that shareholders' interests are well served. Ocumetics Technology's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Ocumetics Technology's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Dean Burns, CEO President | ||
| Doyle Stulting, Chief Director | ||
| Garth Webb, Chairman Founder | ||
| Mark Lee, Pres CEO |
Ocumetics Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Ocumetics Technology a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -11.23 | ||||
| Return On Asset | -0.79 | ||||
| Current Valuation | 39.74 M | ||||
| Shares Outstanding | 119.77 M | ||||
| Shares Owned By Insiders | 45.68 % | ||||
| Number Of Shares Shorted | 10.96 K | ||||
| Price To Book | 400.96 X | ||||
| EBITDA | (2.59 M) | ||||
| Net Income | (3.64 M) | ||||
| Total Debt | 945.33 K |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Ocumetics Stock Analysis
When running Ocumetics Technology's price analysis, check to measure Ocumetics Technology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ocumetics Technology is operating at the current time. Most of Ocumetics Technology's value examination focuses on studying past and present price action to predict the probability of Ocumetics Technology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ocumetics Technology's price. Additionally, you may evaluate how the addition of Ocumetics Technology to your portfolios can decrease your overall portfolio volatility.